Literature DB >> 16253220

Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?

Azize Sener1, Derya Ozsavci, Rabia Oba, Gulderen Yanikkaya Demirel, Fikriye Uras, K Turay Yardimci.   

Abstract

OBJECTIVES: The circulating lipoproteins may cause some abnormalities in platelet composition and function in hypercholesterolemia. The aim of this study was to investigate whether platelet apoptosis, platelet activation, platelet aggregation, platelet-leukocyte aggregate (PLA) formation and lipid peroxidation occur simultaneously in hyperlipidemia. DESIGN AND METHODS: Expression of GpIIb/IIIa (CD41a), P-selectin (CD62-P), platelet-bound fibrinogen (antifibrinogen), platelet membrane phosphatidylserine (PS), platelet-monocyte aggregates (mono-PLA) and platelet-neutrophil aggregates (neut-PLA) was measured in eight hyperlipidemic and eight normal subjects using flow cytometry. ADP (10 microM) was used to activate platelets. Furthermore, ADP induced platelet aggregation responses, platelet malondialdehyde (MDA) and glutathione (GSH) levels were determined.
RESULTS: Before platelet activation, platelet CD62-P, antifibrinogen, annexin-V, mono-PLA, neut-PLA and platelet MDA levels as well as platelet aggregation responses in the hyperlipidemics were significantly higher than those in the controls (P<0.01, P<0.01, P<0.01, P<0.001, P<0.001, P<0.01, P<0.001, respectively), whereas GpIIb/IIIa expression and GSH levels were not different significantly (P > 0.05). In the control group, CD62-P, antifibrinogen and annexin-V levels increased significantly after ADP activation (P<0.05, P<0.05, P<0.01, respectively). In hyperlipidemic subjects, annexin-V expression increased significantly after activation (P<0.01), whereas expression of GpIIb/IIIa, CD62-P and antifibrinogen remained unchanged (P>0.05). The levels of total cholesterol (T-CHO), low density lipoprotein cholesterol (LDL-C), serum fibrinogen (S-FGN) and high density lipoprotein cholesterol (HDL-C) in patients were found to be correlated with platelet CD62-P, antifibrinogen, annexin-V, mono-PLA and MDA.
CONCLUSIONS: In conclusion, it seems that in hyperlipidemia, some platelets are in an activated state in circulation, and that increased lipid peroxidation, early apoptosis, platelet-leukocytes aggregate formation and platelet aggregation altogether accompany this process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16253220     DOI: 10.1016/j.clinbiochem.2005.09.005

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  15 in total

1.  Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease.

Authors:  Paul A Gurbel; Udaya S Tantry
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02

2.  Fasting lipid and lipoproteins concentrations in pregnant women with a history of migraine.

Authors:  Bizu Gelaye; Gloria T Larrabure-Torrealva; Chunfang Qiu; Miguel Angel Luque-Fernandez; B Lee Peterlin; Sixto E Sanchez; Michelle A Williams
Journal:  Headache       Date:  2015-04-22       Impact factor: 5.887

3.  Chromium picolinate inhibits cholesterol-induced stimulation of platelet aggregation in hypercholesterolemic rats.

Authors:  A A Seif
Journal:  Ir J Med Sci       Date:  2014-03-15       Impact factor: 1.568

4.  Elevation of monocyte-platelet aggregates is an early marker of type 2 diabetes.

Authors:  Zsófia Patkó; Albert Császár; György Acsády; Iván Ory; Eva Takács; József Fűrész
Journal:  Interv Med Appl Sci       Date:  2012-12-27

5.  The effect of trans-resveratrol on platelet-neutrophil complex formation and neutrophil burst in hypercholesterolemic rats.

Authors:  Ayşe Yeşim Göçmen; Durmuş Burgucu; Ihsan Karadoğan; Ayşen Timurağaoğlu; Saadet Gümüşlü
Journal:  Exp Clin Cardiol       Date:  2013

6.  Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits.

Authors:  Hideki Ito; Kenji Uehara; Yutaka Matsumoto; Ayako Hashimoto; Chifumi Nagano; Manabu Niimi; Goro Miyakoda; Keisuke Nagano
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

7.  Hyperlipidemia in migraine: Is it more frequent in migraineurs?

Authors:  Alia Saberi; Hamid Reza Hatamian; Ehsan Kazemnejad; Nasim Ghorbannejad
Journal:  Iran J Neurol       Date:  2011

8.  Naringin administration inhibits platelet aggregation and release by reducing blood cholesterol levels and the cytosolic free calcium concentration in hyperlipidemic rabbits.

Authors:  Yang Xiao; Lai-Lai Li; Yan-Yan Wang; Jing-Jing Guo; Wen-Ping Xu; Yan-Yan Wang; Yi Wang
Journal:  Exp Ther Med       Date:  2014-06-20       Impact factor: 2.447

9.  Clinical Response to Valproate in Patients with Migraine.

Authors:  Mizuki Ichikawa; Hirotaka Katoh; Tatsuya Kurihara; Masakazu Ishii
Journal:  J Clin Neurol       Date:  2016-10       Impact factor: 3.077

10.  Modulation of platelet functions by crude rice (Oryza sativa) bran policosanol extract.

Authors:  Wai-Teng Wong; Maznah Ismail; Mustapha Umar Imam; Yi-Da Zhang
Journal:  BMC Complement Altern Med       Date:  2016-07-28       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.